United Therapeutics Corporation
United Therapeutics Enters into New Credit Agreement and Terminates Previous One
Summary
On April 25, 2025, United Therapeutics Corporation entered into a new Credit Agreement with lenders and Wells Fargo Bank, providing an unsecured, revolving credit facility of up to $2.5 billion. The new agreement matures in five years, with an option to extend the maturity date by one year up to two times. On the same day, the company paid off and terminated its 2022 Credit Agreement without any penalties. The new Credit Agreement includes customary affirmative and negative covenants, as well as events of default, including a change of control. The Credit Agreement allows the company to refinance existing indebtedness and use the proceeds for working capital and general corporate purposes.
Profitelligence Alerts
Get alerts for UTHR
Be first to know when United Therapeutics Corporation files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About United Therapeutics Corporation
United Therapeutics Corporation is a biotechnology company engaged in the development and commercialization of innovative pharmaceutical products. Primarily focusing on therapies to address unmet medical needs for chronic and life-threatening conditions, United Therapeutics is notable for its contributions in the field of pulmonary arterial hypertension (PAH). The company offers a portfolio of products that include both oral and inhaled treatments, such as Remodulin and Tyvaso, providing critical care solutions that significantly improve patients' quality of life. Additionally, they are investing in innovative technologies such as organ manufacturing and regenerative medicine, showcasing a commitment to future medical advances. Headquartered in Silver Spring, Maryland, United Therapeutics operates across various stages of drug research, from clinical trials to post-market analysis. As a key player in the biotechnology industry, the company holds an influential position, contributing to significant advancements in therapeutic solutions and reinforcing its role in the healthcare market by addressing complex medical challenges and patient needs effectively.
Official SEC Documents
Advertisement